Renaissance Venture Capital

Strata Oncology, Inc. is a precision oncology company focused on improving cancer care by increasing patient access to clinical trials and expediting drug approvals. The company operates a national precision oncology platform that connects patient screening to streamlined enrollment in mutation-matched clinical trials. Strata collaborates with major healthcare systems to facilitate the genomic sequencing of cancer patients' biopsies in high-throughput laboratories, providing oncologists with timely tumor profiles that inform treatment decisions. Its offerings include The Strata Trial, StrataNGS for targeted DNA and RNA sequencing, and StrataPOINT, which integrates electronic medical records with molecular data to ensure comprehensive testing and follow-up for eligible patients. Strata also manages a portfolio of pharmaceutical-sponsored trials tailored to specific biomarkers and operates the Strata Precision Oncology Network, a collaborative effort among cancer centers to advance precision medicine. Founded in 2015 and headquartered in Ann Arbor, Michigan, Strata was previously known as Strata Oncology Research, Inc. until its name change in May 2016.

Autobooks, Inc. is a provider of integrated payment and accounting software tailored for small businesses. Founded in 2015 and based in Detroit, Michigan, the company offers an intelligent, cloud-based platform that seamlessly integrates with bank accounts, facilitating cash flow management, account reconciliation, and business growth. Through its services, Autobooks enables financial institutions to deliver essential back-office functions and an e-commerce platform directly within their digital banking channels. Its product suite includes features for invoicing, bill pay, merchant services, treasury products, and automated accounting, all designed to simplify financial management for small businesses. The company, originally known as Automated Booking, Inc., rebranded to Autobooks, Inc. in March 2018.

Strata Oncology, Inc. is a precision oncology company focused on improving cancer care by increasing patient access to clinical trials and expediting drug approvals. The company operates a national precision oncology platform that connects patient screening to streamlined enrollment in mutation-matched clinical trials. Strata collaborates with major healthcare systems to facilitate the genomic sequencing of cancer patients' biopsies in high-throughput laboratories, providing oncologists with timely tumor profiles that inform treatment decisions. Its offerings include The Strata Trial, StrataNGS for targeted DNA and RNA sequencing, and StrataPOINT, which integrates electronic medical records with molecular data to ensure comprehensive testing and follow-up for eligible patients. Strata also manages a portfolio of pharmaceutical-sponsored trials tailored to specific biomarkers and operates the Strata Precision Oncology Network, a collaborative effort among cancer centers to advance precision medicine. Founded in 2015 and headquartered in Ann Arbor, Michigan, Strata was previously known as Strata Oncology Research, Inc. until its name change in May 2016.

Next Coast Ventures, established in 2015 and headquartered in Austin, Texas, is a venture capital firm focusing on early-stage technology companies. It invests in 'Next Coast' markets, targeting high-growth startups in Texas and other non-coastal regions. The firm's investment strategy is guided by macro trends and themes, with a preference for sectors such as information technology, workplace, healthcare, retail, and marketplace software. Next Coast Ventures provides not only capital but also hands-on support and industry connections to its portfolio companies, aiming to facilitate their growth and success.

Cirius Therapeutics, Inc. is a clinical-stage pharmaceutical company dedicated to developing and commercializing therapies for liver and metabolic diseases. Founded in 2015 and headquartered in San Diego, California, the company focuses on its lead product candidate, MSDC-0602K, an oral small molecule currently undergoing Phase 2b clinical trials for the treatment of nonalcoholic steatohepatitis (NASH) with fibrosis. This next-generation insulin sensitizer aims to address the underlying pathophysiology of NASH, a condition characterized by fat accumulation and inflammation in the liver that can lead to severe complications such as cirrhosis and liver cancer. Cirius Therapeutics is committed to providing innovative solutions to healthcare providers for managing liver and metabolic diseases.

Millendo Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for endocrine diseases resulting from hormone dysregulation. The company focuses on creating distinct and transformative therapies that address significant unmet medical needs in this area. By leveraging scientific advancements, Millendo aims to develop novel compounds that can effectively treat complex conditions, ultimately enhancing clinical care and improving the quality of life for patients, families, and caregivers.

Atlas Venture, established in 1980, is a Cambridge, Massachusetts-based venture capital firm with a global presence. It manages over $2 billion in committed capital across multiple funds. The firm specializes in early-stage investing, focusing on life sciences and technology sectors. Atlas Venture creates and invests in biotech startups led by promising entrepreneurs, aiming to build scalable businesses and realize value. It typically invests $500,000 to $5 million in seed and early-stage rounds, with follow-on financing potentially reaching $10 to $20 million per company. Since 1995, Atlas Venture has been involved with over 350 companies, with 50 acquisitions and 40 IPOs.

ArborMetrix, Inc. is a data analytics and technology company focused on enhancing healthcare outcomes and advancing research through its innovative platform. Founded in 2011 and headquartered in Ann Arbor, Michigan, ArborMetrix offers a range of solutions for the healthcare industry, including data collection and integration, performance measurement, and analytics. Its products, such as EpisodeMetrix, provide critical insights into payer claims data, helping healthcare payers and at-risk providers manage costs and improve specialty care quality. The company also offers RegistryMetrix, which allows for the creation of specialized clinical registries, and SurgicalMetrix, which analyzes the performance of surgical groups by integrating clinical, financial, and operational data. ArborMetrix serves a diverse clientele that includes specialty societies, medical device manufacturers, pharmaceutical companies, and health systems, delivering actionable insights to optimize clinical outcomes and financial performance.

Swift Biosciences Inc. is a biotechnology company based in Ann Arbor, Michigan, specializing in the development and commercialization of next-generation sequencing (NGS) library preparation kits for genomics and clinical research. The company offers a comprehensive range of products, including RNA library kits, amplicon panels, hybridization capture kits, and specialized kits for cancer gene profiling and COVID-19 testing. Swift Biosciences aims to streamline NGS sample preparation processes through innovative reagents and protocols, enhancing the usability of data obtained from sequencing instruments. Its offerings cater to various applications such as whole-genome sequencing, metagenomics, and the analysis of circulating tumor cells. The company operates through a network of distributors across the Asia Pacific, Europe, the Middle East, and South America, and was incorporated in 2009.

Fidelis SeniorCare, Inc., a managed care company, develops and administers health plans for assisted living residents in Michigan, North Carolina, and Texas. The company offers Medicare advantage special needs plans to cover the health needs of seniors living in nursing homes and assisted living communities; and individuals who require specialized healthcare. Its plans cover on-site primary care team visits, part D prescription drugs, monitoring and managing prescribed medications, transportation to the hospital or physician’s office, and skilled nursing services during a covered Medicare stay; preventive care, screening, vision/dental/hearing, and podiatry services; and emergency room, ambulance, and urgent care services. The company was founded in 2004 and is based in Schaumburg, Illinois.

RPM Ventures, established in 2000 and headquartered in Ann Arbor, Michigan, is an early-stage venture capital firm with a $750 million fund under management. The firm specializes in disrupting multi-billion-dollar markets within sectors such as FinTech, InsurTech, Real Estate Tech, and Mobility & Transportation. RPM Ventures primarily invests in seed and early-stage companies, with a focus on software and technology businesses. The firm targets companies that have the Midwest's Fortune 500 manufacturing base as their primary customer or are based on technology developed at the Midwest's premier research centers. RPM Ventures is recognized as an industry thought leader, with a history of investing in innovative companies that drive market disruption.

Arboretum Ventures, established in 2002, is a Michigan-based venture capital firm with a focus on the healthcare sector. It invests in seed, early, and growth-stage companies across the United States, with a particular emphasis on the Midwest and Michigan. The firm targets healthcare services, medical devices, diagnostics, healthcare IT, therapeutics, technology-based healthcare services, and life science tools. Arboretum Ventures typically invests between $5 million and $15 million in equity per company.